Navigation Links
RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds,Significant Promise for Treating Breast Cancer

IRVING, Texas--(BUSINESS WIRE)--May 15, 2007 - Reata Pharmaceuticals, Inc. today announced the publication of an article in the May 2007 issue of the journal Cancer Research showing that RTA 402, the company's Phase 2 development candidate for cancer, was highly effective in a rigorous animal model of breast cancer and that the drug inhibits signaling activity of STAT3, an important target for new cancer therapies.

The article, "The Novel Triterpenoid C-28 Methyl Ester of 2-Cyano-3, 12-Dioxooleen-1, 9-Dien-28-Oic Acid Inhibits Metastatic Murine Breast Tumor Growth through Inactivation of STAT3 Signaling," was authored by Reata scientific collaborators from the University of Texas M. D. Anderson Cancer Center.

The authors conducted two studies of RTA 402 in the highly rigorous 4T1 mouse model of breast cancer. Few other agents have shown any effect in this animal model, in which tumors grow very rapidly and become widely distributed, or metastasized, throughout the body. In two separate experiments, treatment with RTA 402 was found to have a profound effect in suppressing the growth and spread of these tumors. In a model mimicking the spread of metastatic disease, RTA 402 completely blocked the development of metastases in all animals, whereas untreated animals developed widespread disease. In a second model mimicking the treatment of established breast tumors, RTA 402 provided a 95% reduction in the total tumor burden of treated animals compared with the untreated control group.

Additionally, the authors showed that this activity was occurring in part through inactivation of STAT3 signaling. STAT3 - short for signal transducer and activator of transcription 3 - is increasingly recognized as an important target for cancer therapies. Activated STAT3 is frequently found in patients with breast cancer and other types of tumors. This protein is known to turn on a number of genes associated with cancer growth, invasion, and metastasis. It has also been shown to have a role in preventing the patient's immune system from recognizing and destroying the tumor. It is thought that cancer therapies able to inhibit STAT3 may have profound anti-cancer effects, which may include re-establishing normal immune function against the tumor. The 4T1 animal studies, which are performed in mice that have a normal immune system, provide support for this idea. When researchers examined the spleens of tumor-bearing animals, they found that untreated control animals had a significant reduction in the number of immune cells in their spleens. Animals receiving RTA 402, however, had levels of immune cells that were consistent with healthy, cancer-free animals.

"This paper provides important new data on how RTA 402 works to inhibit the growth and metastasis of cancer," said Warren Huff, CEO of Reata. "The effects on STAT3 shown in this paper, combined with the drugs' proven inhibition of NF-kB, indicate that these agents modulate important and inter-related pathways in cancer cells."

About Reata

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on selecting and discovering promising early drug development opportunities and translating them into successful marketed drugs that target major unmet clinical needs in cancer, inflammation and neurodegenerative disease. The company's two lead programs are entering advanced clinical trials for deadly, late-stage cancers. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform that addresses protein misfolding, a key factor in cancer and neurodegenerative disease, to feed its pipeline of small molecule therapeutic candidates. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded in 2002, Reata is based in the Dallas area. For more information, visit www.reatapharma.com.

Contact

For Reata Pharmaceuticals, Inc.
Kathryn Morris, 845-635-9828
kathryn@kmorrispr.com


'"/>




Related medicine technology :

1. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
2. Gabapentin Shown Effective for Fibromyalgia Pain
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
5. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
6. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
7. Accelreon Pharmas ACE-031Shown to Increase Muscle Mass in Preclinical Studies
8. Cethromycin Shown Effective Against Anthrax in Study
9. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... present at the Cowen and Company 37 th ... Place on Tuesday, March 7, 2017 at 11:20 a.m. ... the presentation can be accessed at http://wsw.com/webcast/cowen38/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/24/2017)... Research and Markets has announced the addition of ... report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies - 2016, ... The research answers the following questions: ... attributes? How are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)... HILL, N.C. , Feb. 24, 2017 /PRNewswire/ ... are exploring ways to increase their self-service capabilities ... Health Care Providers (HCPs). New research ... many pharma organizations have developed self-service website portals ... electronically.  This is just one of many findings ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association ... Annual Meeting. KLS is a longtime supporter of the event. , "We are ... Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... National Institute for Health and Care Excellence (NICE) framework. The agreement allows ... Service (NHS) to search, order and purchase medical and healthcare-related content through ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, a ... Mahon was named a 2017 Top Patient Rated Henderson Dentist by Find ... that recognizes local physicians and dentists who have earned high ratings and superior patient ...
Breaking Medicine News(10 mins):